OBJECTIVES: To compare the disease status and outcomes of patients with PsA receiving adalimumab and etanercept monotherapy in the US.  METHODS: A retrospective medical chart-review of PsA patients was conducted to collect de-identified data for those recently treated with a biologic as part of usual care. Physicians (rheumatologists) were screened for duration of practice (3-30yrs) and patient volume (incl. >5 PsA biologic patients/month) and recruited from a large panel to be geographically representative. Eligible patient charts (≥3) were randomly selected from a sample of patients visiting each center/practice during the screening period. Physicians abstracted patient diagnosis, treatment patterns/dynamics and patient symptomatology/disease status/outcomes. Patients on adalimumab/etanercept monotherapy were analyzed. RESULTS: CONCLUSIONS: PsA patients on adalimumab monotherapy were slightly older and on adalimumab for fewer average months than patients on etanercept.  Most (>90%) were on their first biologic. The adalimumab group appeared to have a slightly higher disease burden and comorbidities. Factors influencing the observed patterns (including the choice of specific biologic for targeted patient profiles) may warrant further scrutiny to optimize therapeutic interventions and improve outcomes.